MétaCan
← all works

Novel Alzheimer risk genes determine the microglia response to amyloid‐β but not to TAU pathology

2020· article· en· 298 citations· W3000035810 on OpenAlex· 10.15252/emmm.201910606

Why is this work in the frame?

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

Canadian funderA Canadian agency funded it. The work may carry no Canadian affiliation at all.

No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.

The three-model screen

all 1,000 screened works →

All three models called this out of scope.

stratum: fund_new · design weight: 1678.90 (the sample is stratified; any rate computed without the weight is wrong)
Claude Opus 4.8OUT
genre: empirical
about Canada: no
confidence: high

Mouse-model transcriptomics of Alzheimer risk genes and microglial response; the object is disease biology.

GPT-5.6 (high)OUT
genre: empirical
about Canada: no
confidence: high

The study investigates Alzheimer disease biology and genetic risk mechanisms, not research practice.

Grok 4.5OUT
genre: empirical
about Canada: no
confidence: high

Biomedical genetics of Alzheimer risk genes and microglial response to pathology.

Abstract

Abstract Polygenic risk scores have identified that genetic variants without genome‐wide significance still add to the genetic risk of developing Alzheimer's disease (AD). Whether and how subthreshold risk loci translate into relevant disease pathways is unknown. We investigate here the involvement of AD risk variants in the transcriptional responses of two mouse models: APPswe/PS1 L166P and Thy‐TAU22. A unique gene expression module, highly enriched for AD risk genes, is specifically responsive to Aβ but not TAU pathology. We identify in this module 7 established AD risk genes ( APOE , CLU , INPP5D , CD33, PLCG2 , SPI1, and FCER1G ) and 11 AD GWAS genes below the genome‐wide significance threshold ( GPC2, TREML2, SYK, GRN, SLC2A5, SAMSN1, PYDC1, HEXB, RRBP1, LYN, and BLNK), that become significantly upregulated when exposed to Aβ. Single microglia sequencing confirms that Aβ, not TAU, pathology induces marked transcriptional changes in microglia, including increased proportions of activated microglia. We conclude that genetic risk of AD functionally translates into different microglia pathway responses to Aβ pathology, placing AD genetic risk downstream of the amyloid pathway but upstream of TAU pathology.

Stored with the screening record, where it is evidence for the labels above.

The record

Venue
EMBO Molecular Medicine
Topic
Neuroinflammation and Neurodegeneration Mechanisms
Field
Neuroscience
Canadian institutions
Funders
Fondation pour la Recherche sur AlzheimerVlaams Instituut voor BiotechnologieFonds Wetenschappelijk OnderzoekVlaamse regeringVlaamse OverheidKU LeuvenAlzheimer SocietyAgence Nationale de la RechercheUK Research and InnovationMedical Research CouncilAlzheimer's Association
Keywords
MicrogliaPathologyAmyloid (mycology)Tau pathologyAmyloid βMedicineGeneAlzheimer's diseaseBiologyNeuroscienceDiseaseInflammationImmunologyGenetics
Has abstract in OpenAlex
yes